Li et al reported a prognostic model for a pediatric patient with acute myeloid leukemia (AML). This can help to identify a patient who may require more aggressive management. The authors are from Chinese Academy of Medical Sciences and Peking Union Medical College in Tianjin, China.
Patient selection: pediatric patient with AML (age range from 3 to 14 years in study populations)
Parameters:
(1) age at diagnosis in years
(2) -7 or del(7q)
(3) -5 or del(5q)
(4) CBF fusion gene
(5) FLT3-ITD and NPM1 status
(6) CEBPA biallelic mutation (CCAAT enhancer binding protein alpha)
(7) WT1 mutation
Parameter
Finding
Points
age at diagnosis
< 2 years
0
>= 2 years
0.38
chromosome 5 or 7
-7/del(7q) OR -5/del(5q)
0.862
neither
0
CBF fusion gene
absent
0
present
-1.452
FLT3-ITD and NPM1
FLT3-ITD(-) and NPM1(-)
0
FLT3-ITD(-) and NPM1(+)
-1.252
FLT3-ITD(+) and NPM1(-)
0.054
FLT3-ITD(+) and NPM1(+)
-0.512
CEBPA biallelic mutation
absent
0
present
-1.166
WT1 mutation
absent
0
present
0.553
risk score =
= SUM(points for all of the parameters)
Score
Risk Group
5-Year Overall Survival
< -1.018
low
86%
-1.018 to 0.38
intermediate
66.5%
> 0.38
high
36.5%
To read more or access our algorithms and calculators, please log in or register.
